Chemomab Therapeutics Ltd.

Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.

CMMB | US

Overview

Corporate Details

ISIN(s):: US16385C1045 (+1 more)
LEI:
Country:: United States of America
Address:: KIRYAT ATIDIM, BUILDING 7, 6158002 TEL AVIV
Website:: https://www.chemomab.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's approach is centered on its discovery of the soluble protein CCL24 as a key driver of the vicious cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class, dual-activity monoclonal antibody designed to bind to and neutralize CCL24. Nebokitug has demonstrated disease-modifying potential and a favorable safety profile in multiple clinical trials for severe fibrotic diseases. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial in primary sclerosing cholangitis (PSC), for which nebokitug has received FDA Fast Track and Orphan Drug designations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chemomab Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemomab Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Chemomab Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Labomar A CDMO developing custom supplements, medical devices & cosmetics for third-party clients.	Italy	LBM
Laboratorio Farmaceutico Erfo Full-service contract manufacturer of private label supplements and medical devices.	Italy	ERFO
Laboratorio Reig Jofre S.A. A pharmaceutical company making essential health products accessible in over 70 countries.	Spain	RJF
Laboratorios Farmaceuticos Rovi S.A. Integrated pharma firm developing prescription drugs and offering contract manufacturing services.	Spain	ROVI
LakeShore Biopharma Co., Ltd. Develops vaccines and therapeutic biologics for infectious diseases and cancer.	United States of America	LSB
Lantern Pharma Inc. Leverages AI and machine learning to discover and develop targeted cancer therapies.	United States of America	LTRN
Lantheus Holdings, Inc. Develops radiopharmaceutical diagnostics and therapies to help clinicians fight disease.	United States of America	LNTH
LAVA Therapeutics NV Develops bispecific gamma delta T cell engagers for solid and hematologic cancers.	United States of America	LVTX
Lavipharm S.A. Develops & distributes Rx/OTC medicines, supplements & cosmetics for key therapeutic areas.	Greece	LAVI
LB PHARMACEUTICALS INC Clinical-stage biopharma developing oral therapies for neuropsychiatric diseases like schizophrenia.	United States of America	LBRX